1. Medtech Insight
  2. >>Policy & Regulation

Global Device Approvals, Weekly Snapshot: Transcranial Stimulator For Alzheimer's, And More

 
• By David Filmore and Reed Miller

A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. Among the five added this week, Neuronix's NeuroAD Non Invasive Cortical Enhancer technology was approved in Australia for use in Alzheimer's patients, in combination with "tailored cognitive therapy."

Approved

Details and links for all five new approvals are included in the table below, and historical data on global device approvals can be found in the full Approvals Tracker. In the US, the table only includes original PMAs, panel-track PMA supplements and de novo classifications. (No panel-track supplements were approved last week by FDA.) During the period, FDA cleared 58 510(k)s, and it approved 8 non-panel-track PMA supplements and 42 30-day notices for certain manufacturing modifications.

Global Device Approvals, Sept. 17-23, 2018

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 
• By Amanda Maxwell

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.